Comparable cumulative exposure and amyloid reduction following donanemab standard and modified titration dosing in participants with early symptomatic Alzheimer’s disease from TRAILBLAZER‐ALZ 6
The standard and modified dosing arms in TRAILBLAZER-ALZ 6 achieved similar cumulative doses and exposures (AUC) and provided consistent C<sub>av,ss</sub> associated with amyloid plaque reduction. Bridging based on PK/PD for these two regimens was ascertained.
Authors
- Ivelina Gueorguieva (ORCID: https://orcid.org/0000-0001-5864-8924)
- Sergey Shcherbinin (ORCID: https://orcid.org/0009-0003-9451-1230)
- Emel Serap Monkul Nery
- John Randall Sims (ORCID: https://orcid.org/0009-0009-5090-7886)
- Kay Hoong Chow
- Dawn A. Brooks
- Hong Wang
Institutions
- Eli Lilly (United States) (US)
- Eli Lilly (United Kingdom) (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108108
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00